Mary Canning
Directeur/Membre du Conseil chez Caldan Therapeutics Ltd.
Profil
Mary Canning is currently a Director at Caldan Therapeutics Ltd., Lunac Therapeutics Ltd., Transine Therapeutics Ltd., and a Partner at Epidarex Capital Partners LLC.
She is also a Board observer at Leucid Bio Ltd.
Previously, she served as a Board observer at Curve Therapeutics Ltd.
Dr. Canning obtained her doctorate degree from The University of Edinburgh in 2000.
Postes actifs de Mary Canning
Sociétés | Poste | Début |
---|---|---|
Epidarex Capital Partners LLC
Epidarex Capital Partners LLC Investment ManagersFinance Epidarex Capital Partners LLC (Epidarex Capital) is a venture capital firm founded in 2010 by Kyparissia Sirinakisvin. The firm is headquartered in Bethesda, Maryland. | Analyste en capital-investissement | 01/02/2013 |
Lunac Therapeutics Ltd.
Lunac Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Lunac Therapeutics Ltd. engages in the identification and development of anticoagulants. The company was founded by Helen Philippou and Richard Foster on April 18, 2018 and is headquartered in Leeds, the United Kingdom. | Directeur/Membre du Conseil | 20/09/2019 |
Caldan Therapeutics Ltd.
Caldan Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Caldan Therapeutics Ltd. provides novel therapeutics targeting free fatty acid. It focuses on developing drugs in order to deliver anti-diabetic effects in multiple tissues and organs. The company was founded by Graeme Milligan and Trond Ulven and is headquartered in Edinburgh, the United Kingdom. | Directeur/Membre du Conseil | 01/04/2021 |
Leucid Bio Ltd.
Leucid Bio Ltd. Miscellaneous Commercial ServicesCommercial Services Leucid Bio Ltd. is a clinical-stage biotechnology company based in London, UK. The British company develops novel, lateral car cell therapies for the treatment of refractory cancers, with a focus on developing next-generation cell therapies for the benefit of individuals with hard-to-treat solid tumors. The company's operations are based at Guys Hospital, enabling them to maintain a patient-centric focus. Leucid's goal is to develop CAR-T therapies with more durable responses, improving treatment outcomes and saving the lives of patients with refractory cancers. Leucid was established to translate 20 years of Kings College research in the CAR-T field and is led by a highly experienced management team, including scientific founder John Maher. Filippo Joseph Petti has been the CEO of the company since 2023. | Directeur/Membre du Conseil | - |
Transine Therapeutics Ltd.
Transine Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Transine Therapeutics Ltd. is an RNA platform company based in Cambridge, UK. The British company is developing a novel class of therapeutic RNAs called SINEUPs, which can upregulate protein expression with a superior level of control and specificity across an unprecedented range of diseases and applications. The company's proprietary technology allows them to address diseases that have been beyond the reach of small molecules, conventional biologics, or gene therapies. The SINEUP platform boosts the expression of almost any chosen target protein by binding precisely to the mRNA that encodes it and enhancing its translation. This technology massively extends the druggable proteome and represents an entirely new mechanism of action, ideally suited to address currently hard-to-treat diseases. The company was founded in 2018 by Stefano Gustincich and Piero Carninci. Jan Thirkettle has been the CEO of the company since 2021. | Private Equity Investor | 01/04/2022 |
Anciens postes connus de Mary Canning
Sociétés | Poste | Fin |
---|---|---|
Curve Therapeutics Ltd.
Curve Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Curve Therapeutics Ltd. operates as a drug-discovery company. It engages on the development of innovative technologies to address undruggable disease-modifying targets, with an in-house focus on cancer. The company was founded in 2019 and is headquartered in London, the United Kingdom. | Directeur/Membre du Conseil | - |
Formation de Mary Canning
The University of Edinburgh | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Entreprise privées | 6 |
---|---|
Epidarex Capital Partners LLC
Epidarex Capital Partners LLC Investment ManagersFinance Epidarex Capital Partners LLC (Epidarex Capital) is a venture capital firm founded in 2010 by Kyparissia Sirinakisvin. The firm is headquartered in Bethesda, Maryland. | Finance |
Lunac Therapeutics Ltd.
Lunac Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Lunac Therapeutics Ltd. engages in the identification and development of anticoagulants. The company was founded by Helen Philippou and Richard Foster on April 18, 2018 and is headquartered in Leeds, the United Kingdom. | Health Technology |
Caldan Therapeutics Ltd.
Caldan Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Caldan Therapeutics Ltd. provides novel therapeutics targeting free fatty acid. It focuses on developing drugs in order to deliver anti-diabetic effects in multiple tissues and organs. The company was founded by Graeme Milligan and Trond Ulven and is headquartered in Edinburgh, the United Kingdom. | Commercial Services |
Leucid Bio Ltd.
Leucid Bio Ltd. Miscellaneous Commercial ServicesCommercial Services Leucid Bio Ltd. is a clinical-stage biotechnology company based in London, UK. The British company develops novel, lateral car cell therapies for the treatment of refractory cancers, with a focus on developing next-generation cell therapies for the benefit of individuals with hard-to-treat solid tumors. The company's operations are based at Guys Hospital, enabling them to maintain a patient-centric focus. Leucid's goal is to develop CAR-T therapies with more durable responses, improving treatment outcomes and saving the lives of patients with refractory cancers. Leucid was established to translate 20 years of Kings College research in the CAR-T field and is led by a highly experienced management team, including scientific founder John Maher. Filippo Joseph Petti has been the CEO of the company since 2023. | Commercial Services |
Curve Therapeutics Ltd.
Curve Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Curve Therapeutics Ltd. operates as a drug-discovery company. It engages on the development of innovative technologies to address undruggable disease-modifying targets, with an in-house focus on cancer. The company was founded in 2019 and is headquartered in London, the United Kingdom. | Commercial Services |
Transine Therapeutics Ltd.
Transine Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Transine Therapeutics Ltd. is an RNA platform company based in Cambridge, UK. The British company is developing a novel class of therapeutic RNAs called SINEUPs, which can upregulate protein expression with a superior level of control and specificity across an unprecedented range of diseases and applications. The company's proprietary technology allows them to address diseases that have been beyond the reach of small molecules, conventional biologics, or gene therapies. The SINEUP platform boosts the expression of almost any chosen target protein by binding precisely to the mRNA that encodes it and enhancing its translation. This technology massively extends the druggable proteome and represents an entirely new mechanism of action, ideally suited to address currently hard-to-treat diseases. The company was founded in 2018 by Stefano Gustincich and Piero Carninci. Jan Thirkettle has been the CEO of the company since 2021. | Health Technology |